Results 51 to 60 of about 1,312,052 (154)

Small-molecule inhibitors get pro-inflammatory TNF into shape

open access: yes, 2020
Newly discovered small-molecule TNF inhibitors serve as antagonists of pro-inflammatory TNF signalling by uniquely harnessing the conformational plasticity of trimeric TNF.
Dirk Elewaut   +5 more
core   +1 more source

Golimumab (anti-TNF monoclonal antibody): where we stand today

open access: yesHuman Vaccines & Immunotherapeutics, 2021
Tumor necrosis factor (TNF) is a pro-inflammatory cytokine and its overexpression has been implicated in the pathophysiology of several chronic immune-mediated inflammatory diseases.
Ana Teresa Melo   +2 more
doaj   +1 more source

A Novel Competitive Binding Screening Assay Reveals Sennoside B as a Potent Natural Product Inhibitor of TNF-α

open access: yesBiomedicines, 2021
Natural products (NPs) have played a significant role in drug discovery for diverse diseases, and numerous attempts have been made to discover promising NP inhibitors of tumor necrosis factor α (TNF-α), a major therapeutic target in autoimmune diseases ...
Lei Peng   +4 more
doaj   +1 more source

Development of a novel class of CBP/EP300 bromodomain inhibitors which block TNF-α induced NFκB signaling [PDF]

open access: yes
Tumor Necrosis Factor α (TNF-α) is an inflammatory cytokine that is a key mediator in autoimmune disorders such as Crohn’s disease and rheumatoid arthritis (RA).
Amedeo, Caflisch   +9 more
core   +1 more source

TNF inhibitors and extraarticular RA Personal non-commercial use only [PDF]

open access: yes, 2020
. Objective. The aims of this study were to evaluate whether treatment with tumor necrosis factor (TNF) inhibitors in patients with rheumatoid arthritis (RA) affects the risk of developing severe extraarticular rheumatoid arthritis (ExRA ...
Ingemar F Jacobsson   +8 more
core  

Tumor necrosis factor (TNF) inhibitors

open access: yes, 2016
The tumor necrosis factor (TNF) inhibitors are protein constructs which bind and inactivate TNF. They are members of a group of proteins commonly termed biological response modifiers (BRMs) or biological disease-modifying antirheumatic drugs (bDMARDs ...
Mahler, Stephen M.   +2 more
core   +1 more source

Effect of tumor necrosis factor-α inhibitors on ambulatory 24-h blood pressure

open access: yesBlood Pressure, 2017
Tumor necrosis factor alpha (TNF-α) inhibitors are increasingly being used in inflammatory rheumatic diseases (IRD). The risk of cardiovascular disease is elevated in patients with IRD and TNF-α inhibitors reduce this risk.
Chagai Grossman   +4 more
doaj   +1 more source

Risk of Tuberculosis in Children with Juvenile Idiopathic Arthritis: A Nationwide Population-Based Study in Taiwan. [PDF]

open access: yesPLoS ONE, 2015
We aimed to determine the risk of tuberculosis in children with juvenile idiopathic arthritis (JIA) in Taiwan.We used the Taiwan National Health Insurance Research Database (NHIRD) to conduct a nested case-control study.
Yi-Chen Hsin   +5 more
doaj   +1 more source

Clinical characteristics of treatment-resistant spondyloarthritis patients treated with multiple biologic pathways

open access: yesUlusal Romatoloji Dergisi
Objective: With increasing use of biologics targeting multiple pathways in treatment-resistant spondyloarthritis (SpA), understanding patient characteristics has become crucial.
Gözde Duygu İşbilir   +10 more
doaj   +1 more source

Clinical information on AS patients who resumed TNF inhibitors.

open access: yes, 2016
Clinical information on AS patients who resumed TNF inhibitors.
Yong-Gil Kim (2622202)   +17 more
core   +1 more source

Home - About - Disclaimer - Privacy